ALSO NOTED: Merck clings to AstraZeneca drug rights; GSK recalls malaria drug, stops trial;

> Merck said it would not relinquish its rights to a host of AstraZeneca drugs it markets for the British drug maker in the U.S., including blockbuster heartburn meds Nexium and Prilosec; AstraZeneca had offered to buy back the rights. Report

> AstraZeneca officially asked the FDA to extend approval of its schizophrenia drug Seroquel to cover major depressive disorder as well; the company last month submitted apps for Seroquel use in bipolar disorder. Report

> GlaxoSmithKline will recall its malaria drug Lapdap and halt development of another malaria treatment, after halting a clinical trial that showed both meds increased the risk of anemia. Release

> The FDA gave the nod to AstraZeneca's acid reflux med Nexium for use in kids 1 to 11 years. Report

> The FDA also approved Jazz Pharma's once-a-day version of Luvox, a treatment for social anxiety and obsessive compulsive disorder. Report

> Looking to expand the market for its anti-insomnia pill ramelteon (otherwise known as Rozerem), Takeda Pharmaceutical applied for approval from Japanese regulators. Release

> Generics maker Teva Pharmaceutical plans to appeal a court ruling that upheld a Procter & Gamble patent on the osteoporosis drug Actonel. Report

And Finally… Researchers have found a gene that can block the spread of HIV. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.